- Report
- May 2024
- 135 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- July 2022
- 203 Pages
Global
From €6680EUR$7,150USD£5,651GBP
- Report
- January 2023
- 124 Pages
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 134 Pages
Middle East, Africa
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 146 Pages
North America
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 153 Pages
Europe
From €3223EUR$3,450USD£2,727GBP
- Report
- October 2022
- 209 Pages
Global
From €4157EUR$4,450USD£3,517GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Tolterodine is a medication used to treat symptoms of overactive bladder, such as frequent urination, urgency, and incontinence. It is a muscarinic receptor antagonist, which works by blocking the action of a chemical messenger in the muscles of the bladder. Tolterodine is part of a class of drugs known as antimuscarinics, which are commonly used to treat urological disorders.
Tolterodine is available in both immediate-release and extended-release formulations, and is typically taken twice daily. Common side effects include dry mouth, constipation, and blurred vision. It is important to note that tolterodine should not be used in patients with certain medical conditions, such as glaucoma, urinary retention, or uncontrolled narrow-angle glaucoma.
The tolterodine market is a subset of the larger urological disorders drugs market. It is a competitive market, with several companies offering tolterodine products. Some of the companies in the market include Allergan, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more